Literature DB >> 32305723

Prevalence and overlap of somatic symptom disorder, bodily distress syndrome and fibromyalgia syndrome in the German general population: A cross sectional study.

Winfried Häuser1, Constanze Hausteiner-Wiehle2, Peter Henningsen3, Elmar Brähler4, Bjarne Schmalbach4, Frederick Wolfe5.   

Abstract

OBJECTIVE: To study the prevalence and clinical characteristics of Somatic Symptom Disorder (SSD), Bodily Distress Syndrome (BDS) and fibromyalgia syndrome (FMS) and their overlap in the general German population.
METHODS: A cross-sectional nationally representative population survey was performed. 2531 participants (mean age 48.8 ± 17.85 years, 53.3% women) completed the Somatic Symptom Scale SSS-8, the Bodily Distress Syndrome (BDS) 25 checklist, the Whiteley Index 7 (WI-7), the self-administered comorbidity questionnaire and the Michigan Body Map. Case definitions of SSD, BDS and FMS were assigned using established criteria.
RESULTS: 4.5% of participants met the criteria of SSD (SSS - 8 at least one item "bothered very much" and WI- 7 total score ≥ 1). 9.6% met the criteria of single-organ BDS and 1.3% of multi-organ BDS. Prevalence of FMS according to 2016 criteria was 3.4%. 82.3% of FMS cases met any BDS criteria.28.1% of FMS cases satisfied SSD criteria. 28.8% of any BDS cases met the criteria of SSD. 75.1% of SSD cases met the criteria of any BDS. FMS cases reported the highest amount of somatic and psychological symptom burden and health anxieties. There were no differences in age and gender between any BDS and SSD cases. SSD cases reported worse general health and more fibromyalgia-related variables than any BDS cases.
CONCLUSIONS: In the general population, there is a substantial overlap between FMS and BDS, but not of FMS and SSD, and not of SSD and any BDS. Case definitions of the three disorders partially captured different groups in the general population.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bodily distress syndrome; Fibromyalgia syndrome; General population; Prevalence; Somatic symptom disorder; Survey

Year:  2020        PMID: 32305723     DOI: 10.1016/j.jpsychores.2020.110111

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  7 in total

1.  Specialized Biopsychosocial Care in Inpatient Somatic Medicine Units-A Pilot Study.

Authors:  Paul Köbler; Eva K Krauss-Köstler; Barbara Stein; Joachim H Ficker; Martin Wilhelm; Alexander Dechêne; Christiane Waller
Journal:  Front Public Health       Date:  2022-04-12

Review 2.  The Evolution of Fibromyalgia, Its Concepts, and Criteria.

Authors:  Frederick Wolfe; Johannes J Rasker
Journal:  Cureus       Date:  2021-11-29

3.  The effects of music listening on somatic symptoms and stress markers in the everyday life of women with somatic complaints and depression.

Authors:  Anja C Feneberg; Ricarda Mewes; Johanna M Doerr; Urs M Nater
Journal:  Sci Rep       Date:  2021-12-15       Impact factor: 4.379

4.  Mental health specialist video consultations for patients with somatic symptom disorder in primary care: protocol for a randomised feasibility trial (the VISION trial).

Authors:  Markus W Haun; Justus Tönnies; Leike Graue; Mechthild Hartmann; Michel Wensing; Joachim Szecsenyi; Beate Wild; Hans-Christoph Friederich
Journal:  BMJ Open       Date:  2022-04-11       Impact factor: 2.692

5.  Estimated frequency of somatic symptom disorder in general practice: cross-sectional survey with general practitioners.

Authors:  Marco Lehmann; Nadine Janis Pohontsch; Thomas Zimmermann; Martin Scherer; Bernd Löwe
Journal:  BMC Psychiatry       Date:  2022-09-29       Impact factor: 4.144

6.  New challenges in the COVID-19 pandemic.

Authors:  Jess G Fiedorowicz
Journal:  J Psychosom Res       Date:  2020-04-22       Impact factor: 3.006

7.  Health anxiety and attentional bias toward virus-related stimuli during the COVID-19 pandemic.

Authors:  Loreta Cannito; Adolfo Di Crosta; Rocco Palumbo; Irene Ceccato; Stefano Anzani; Pasquale La Malva; Riccardo Palumbo; Alberto Di Domenico
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.